NBC Securities Inc. Makes New Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

NBC Securities Inc. purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 527 shares of the company's stock, valued at approximately $221,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Hurley Capital LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter worth $29,000. Rialto Wealth Management LLC acquired a new stake in IDEXX Laboratories in the fourth quarter worth about $30,000. Colonial Trust Co SC grew its stake in shares of IDEXX Laboratories by 84.8% during the fourth quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after acquiring an additional 39 shares during the last quarter. Kestra Investment Management LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $38,000. Finally, Itau Unibanco Holding S.A. increased its holdings in shares of IDEXX Laboratories by 540.0% during the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after acquiring an additional 81 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

Insider Activity

In related news, Director M Anne Szostak sold 1,046 shares of the firm's stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $513.74, for a total value of $537,372.04. Following the transaction, the director now directly owns 262 shares of the company's stock, valued at approximately $134,599.88. This trade represents a 79.97% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.98% of the company's stock.

IDEXX Laboratories Price Performance

NASDAQ IDXX traded up $7.33 during trading hours on Tuesday, reaching $525.93. The company's stock had a trading volume of 402,495 shares, compared to its average volume of 649,800. The firm has a market capitalization of $42.30 billion, a price-to-earnings ratio of 49.29, a P/E/G ratio of 3.41 and a beta of 1.55. The company's 50-day moving average is $462.00 and its two-hundred day moving average is $441.74. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $530.73.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The business had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. During the same period in the previous year, the business earned $2.71 earnings per share. The business's revenue was up 3.6% compared to the same quarter last year. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analyst Ratings Changes

IDXX has been the topic of several research analyst reports. Morgan Stanley boosted their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Piper Sandler boosted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Finally, Stifel Nicolaus lifted their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research report on Monday, May 19th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $536.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.